FY2025 · period end Dec '25 · from the 10-K filed Apr 7, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 |
|---|---|---|---|---|
| Revenue | $0.01B | $0.01B | $0.01B | $0.02B |
| Gross Profit | $0.01B | $0.01B | $0.00B | $0.01B |
| Operating Income | $0.01B | $0.00B | $0.00B | $0.01B |
| Net Income | $0.01B | $0.00B | $0.00B | $0.01B |
| EPS (Diluted) | $0.15 | $0.06 | $0.10 | $100,112.00 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 |
|---|---|---|---|---|
| Total Assets | $0.03B | $0.02B | $0.02B | — |
| Total Liabilities | $0.00B | $0.00B | $0.00B | — |
| Stockholders' Equity | $0.03B | $0.02B | $0.01B | $0.01B |
| Cash & Equivalents | $0.01B | $0.01B | $0.01B | — |
| Total Debt | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 |
|---|---|---|---|---|
| Operating Cash Flow | negative: -$0.01B | $0.00B | $0.00B | $0.00B |
| Capital Expenditures | — | — | — | — |
| Free Cash Flow | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 |
|---|---|---|---|---|
| Gross Margin | 87.2% | 71.9% | 50.1% | 53.4% |
| Operating Margin | 0.7% | 0.2% | 0.3% | 0.4% |
| Net Margin | 0.7% | 0.3% | 0.3% | 0.4% |
| Return on Equity | 27.0% | 14.8% | 16.5% | 79.8% |
| Return on Assets | 26.0% | 13.7% | 14.3% | — |
| Debt / Equity | — | — | — | — |
Showing the most recent 4 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
One number Anbio Biotechnology later changed — same XBRL tag, both filings linked.
Prepaid Expense, Current·As of Dec 31, 2024
Major restatementwas$5.7M
Revised down in a 20-F.
NNNN is not the only one.
See every restatement we've found across the market — or get an alert the next time NNNN revises a number.
Restatements are detected by comparing every vintage of a fact across all of Anbio Biotechnology's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows NNNN's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling Anbio Biotechnology — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on NNNN yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on NNNN and publish the result to your public profile.
Ask about Anbio Biotechnology
Continue in Workspace — cited answers on NNNN, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs